1. Bioquell PLC Investor Presentation
November 2016
Ian Johnson, Executive Chairman
Michael Roller, Finance Director

2. New Executive team
Ian Johnson, Executive Chairman Ian has spent his business career in life science and was founder and CEO of Biotrace International Plc, which was a listed company until its sale to 3M in December Ian is currently non-executive chairman of Cyprotex PLC and Quantum Pharma PLC and was chairman of Celsis International Ltd and Lumora Ltd. He has served on the boards of various public and private companies in strategic consultancy and business development capacities including: Evans Analytical Group, MyCelx Technologies Corporation and AOI Medical Inc., each AIM traded companies. Ian studied at Cardiff University obtaining a B.Sc. and M.Sc. in Microbiology. He is a chartered biologist, a member of the Royal Society of Biology and the Institute of Directors. Jay LeCoque, Commercial Director Joined the Board on 24th August Jay was CEO of Celsis International Ltd (formerly Celsis International plc) from 2000 to He joined Celsis during its start-up days in 1995 as a Director of Global Business Development. LeCoque previously worked for Baxter Healthcare (NYSE) and AptarGroup (NYSE) in various global sales and marketing roles. LeCoque received his MBA from Northwestern University’s Kellogg Graduate School of Management in 1991 and his BS from Miami University in Oxford, Ohio in Michael Roller, Group Finance Director Joined the Board on 19 March He has previously been Finance Director of a number of quoted companies, most recently Corin Group plc, has significant experience within the Life Sciences sector and is a non-executive director of Filtronic plc. He has also held a number of other senior finance roles in a broad range of listed and private companies. He qualified as an accountant with KPMG.

3. Recent News & Events
June ‘16 Ian Johnson replaces Nigel Keen as non executive Chairman Tender offer completed - £40.8m returned to shareholders August ‘16 Offer period terminated – no satisfactory offers received Nick Adams steps down as CEO Ian Johnson becomes Executive Chairman; Jay LeCoque joins as Commercial Director Interim Announcement September ‘16 Initiated major restructuring of the Group Expect some ‘one off’ costs Expect completion by end of year

4. Focus on core Bio-Decontamination business (95% of Group Revenues)
Life Sciences (80% of bio-decontamination revenues)
new initiatives to drive top line growth
US sales restructured and enhanced
new international business development role
Global Key Account Management
new customer propositions
renewed emphasis on captive consumables & recurring revenues
Healthcare (20% of bio-decontamination revenues)
developing new sales channels for Healthcare market
increasing overlap between Life Science and Healthcare markets
currently US and UK market and mainly RBDS service solution
POD rental in UK
Defence (5% of Group revenues)
non-core business providing CBRN filtration products for vehicles and shelters

5. Summary revenue data £m H1 2016 H1 2015 % Bio-decontamination : 11.1
10.3 8%
Defence
1.0
2.2
(55%)
Total revenues
12.1
12.5
(3%)
Bio-decontamination revenues
Services
6.9
6.3
10%
Systems
4.2
4.0 5%
Recurring Revenues*
62%
61%
Non-UK revenues
8.0
(72%)
7.8
(76%) 3%
US dollars
c. 45%
Euro
c. 27%
* Service revenues are generally recurring / quasi-recurring
Business has longstanding H2 revenues bias

6. Other financial information
Gross margin (%)
46%
42%
Overheads*
(5.2)
Cash overheads (ex FX)**
(4.9)
(5.3)
EBITDA
1.7
1.4
PBT
0.5
0.1
Balance sheet:
Net assets
25.0
64.7***
Net cash
7.3
47.7***
* IFRS overheads, including amortisation of capitalised R&D costs
** overheads expensing R&D and excluding £177k of net FX expense (2015: £84k profit)
*** Includes cash from disposal of TRaC

7. Appendices

8. Bio-decontamination products & services
Systems
Services
Consumables
Mobile systems
Fixed Systems
QUBE (aseptic work station)
Bio - Decon services:
RBDS proactive
RBDS reactive
Preventative maintenance
Repairs
Spares
Validation
Hydrogen peroxide
Biological indicators
Chemical indicators
Rental
POD
Flexible, ‘mix & match’ approach to providing bio-decontamination solutions, predominantly to the international Life Sciences sector

9. Demand driven by regulatory compliance
Bioquell’s bio-decontamination technology is increasingly regulated… …and also enables clients to achieve regulatory compliance EU
ISO 18362
EU regulation of airborne disinfection systems
based on a French National standard (which changed market)
comes into force in February 2017
“Manufacture of cell-based healthcare product – control of microbial risks during processing”
should help drive demand for the QUBE
In the Life Sciences sector, a significant proportion of customers buy from Bioquell to help them achieve regulatory compliance

10. Launch of new fixed (wall-mounted) system
Bioquell FS-1 – or ‘Flat-screen’
fixed decontamination system with consumable
thin, minimised foot-print
demand from clean-room users as well as material airlocks / cleanroom “pass-thrus”
demand increasingly driven by regulations in Life Sciences sector
Completion of the Bioquell product range: fixed, mobile and service

11. Evolving drivers of growth for BQ products & services
complex, rapidly expanding international regulatory environment for the safe production of biologically- sensitive therapeutic products
demand for cost-effective, fast-to-deploy aseptic environments
rapid, aseptic transfer of heat-sensitive materials into cleanrooms
after-sales support & preventative maintenance (NB regulatory requirement)
pressure on costs… …and the use of technology to reduce costs
growth in cell-based healthcare products – eg CAR-T
mitigation of risks and liabilities for complex drug production in hospital pharmacies
Regulatory compliance is a key driver of growth in the international Life Sciences market